A5015184746- Neuroblastoma Research and Treatments
- Renal and related cancers
- Cancer, Hypoxia, and Metabolism
- Ocular Oncology and Treatments
- Renal cell carcinoma treatment
- Sarcoma Diagnosis and Treatment
- Vascular Malformations and Hemangiomas
- Cancer therapeutics and mechanisms
- Lung Cancer Research Studies
- Retinal Development and Disorders
- Childhood Cancer Survivors' Quality of Life
- Glioma Diagnosis and Treatment
- Influenza Virus Research Studies
- Retinal and Macular Surgery
- Hematopoietic Stem Cell Transplantation
- Vascular Malformations Diagnosis and Treatment
- Cancer Diagnosis and Treatment
- Neurofibromatosis and Schwannoma Cases
- Cancer Treatment and Pharmacology
- Prenatal Screening and Diagnostics
- Education, Psychology, and Social Research
- Brain Metastases and Treatment
- Respiratory viral infections research
- Adrenal and Paraganglionic Tumors
- Ocular Infections and Treatments
University Hospital in Motol
2012-2023
Rigshospitalet
2023
Fondazione IRCCS Istituto Nazionale dei Tumori
2023
Charles University
2002-2021
Universitätsklinik für Chirurgie Wien
2013
Society of Paediatric Oncology and Haematology
2011-2012
St Anna Children's Hospital
2010-2011
University College London
2010-2011
Great Ormond Street Hospital
2010-2011
Schneider Children's Medical Center
2010-2011
To evaluate the impact of surgeon-assessed extent primary tumor resection on local progression and survival in patients International Society Pediatric Oncology Europe Neuroblastoma Group High-Risk 1 trial.Patients recruited between 2002 2015 with stage 4 disease > year or 4/4S MYCN amplification < who had completed induction without progression, achieved response criteria for high-dose therapy (HDT), no before were included. Data collected excision, severe operative complications, outcome.A...
In neuroblastoma (NB), the ALK receptor tyrosine kinase can be constitutively activated through activating point mutations or genomic amplification. We studied genetic alterations in high-risk (HR) patients on HR-NBL1/SIOPEN trial to determine their frequency, correlation with clinical parameters, and prognostic impact.Diagnostic tumor samples were available from 1,092 amplification status (n = 330), mutational profile 191), both 571).Genomic (ALKa) was detected 4.5% of cases (41 out 901),...
To reduce the incidence of febrile neutropenia during rapid COJEC (cisplatin, vincristine, carboplatin, etoposide, and cyclophosphamide given in a delivery schedule) induction. In High-Risk Neuroblastoma-1 (HR-NBL1) trial, International Society Paediatric Oncology European Neuroblastoma Group (SIOPEN) randomly assigned patients to primary prophylactic (PP) versus symptom-triggered granulocyte colony-stimulating factor (GCSF; filgrastim).From May 2002 November 2005, 239 16 countries were...
Abstract Background Risk stratification is crucial to treatment decision‐making in neuroblastoma. This study aimed explore factors present at diagnosis affecting outcome patients aged ≥18 months with metastatic neuroblastoma and develop a simple risk score for prognostication. Procedure Data were derived from the European high‐risk 1 (HR‐NBL1)/International Society Paediatric Oncology Neuroblastoma (SIOPEN) trial analysis restricted disease treated prior introduction of immunotherapy....
2 The full, final text of this abstract will be available in Part II the 2011 Annual Meeting Proceedings, distributed onsite at on June 4, 2011, and as a supplement to 20, issue Journal Clinical Oncology.
2 Background: The HR-NBL1 trial of the European SIOP Neuroblastoma Group randomised MAT regimens with primary aim to demonstrate superiority based on event free survival (EFS). Methods: At randomisation closure, 1,577 high-risk neuroblastoma patients (944 males) had been included since 2002; INSS stage 4 disease (1,369 pts) > 1 year, infants (65 and II III (143 any age MYCN amplification. Response eligibility criteria prior after Rapid COJEC Induction (J Clin Oncol, 2010) ± courses TVD...
Series of observations indicate PK/PD variability challenging the accuracy body-weight based busulfan (Bu) dosing schedule for (HSCT) conditioning therapy. The purpose this communication is to describe frequency dose changes in initially body-weight-based fixed IV Bu and emphasize importance TDM.Sixty-two children (ages 2 months-18 years) were treated with doses on body weight myeloablation. TDM utilizing a limited sample strategy (trough concentration immediately before 5th dose, followed...
10521 Background: The effect of complete macroscopic excision (CME) the primary tumour on event free survival (EFS) in high-risk neuroblastoma remains controversial. We therefore investigated influence CME patients enrolled HR-NBL1/SIOPEN Trial and compared pre immunotherapy era. Methods: Eligibility criteria were: inclusion between 2002-2015, stage 4 disease; completion Rapid COJEC induction ± 2 courses TVD; no progression/relapse/death; prior attempt at resection operation data. Intended...
Congenital mesoblastic nephroma (CMN), the most common renal tumor of infancy, is a mesenchymal neoplasm histologically classified into classic, cellular, or mixed types. Most cellular CMNs harbor characteristic ETV6-NTRK3 fusion. Here, we report an unusual congenital presenting in newborn boy with novel EML4-ALK gene fusion revealed by Anchored Multiplex RNA Sequencing Assay. The expands genetic spectrum implicated pathogenesis nephroma, yet another example kinase oncogenic activation...
The aim of this study was to assess retinal toxicity in a rabbit model after carboplatin delivered as repeated transcorneal intravitreal injection, order determine the highest possible safe dose for use human retinoblastoma "seeding" tumor chemotherapy.We used six albino rabbits an vivo experiment and injected 0.008 mg intravitreally (iv) 4 times at two-week intervals. 0.08 mL saline into left eye. We recorded electroretinograms (ERGs) before first injection fourth injection. Platinum...
9511 Background: A semi-quantitative reporting method developed by an international expert panel (J Nucl Med 2009;50:1379) was used to evaluate the role ofI-123 meta-IodoBenzylGuanidine [123I mIBG] imaging in high risk neuroblastoma [HR-NBL]. Method: Patterns of skeletal 123I mIBG uptake were assignednumerical scores (Mscore) ranging from 0 (no metastasis) 72 (diffuse metastases) within 12 body areas as described previously 2009;50:1379). 271 anonymised, paired image data sets acquired at...
Purpose. To determine platinum (Pt) concentrations and area under the concentration versus time curve (AUC) of vitreous humor after periocular or transcorneal intravitreal administration carboplatin in rabbits. Methods. Eighteen albino rabbits were included an vivo experiment. Each animal received a single dose either 30 mg by injection (POI30 group: n=6) 15 (POI15 n=6), 0.05 (TII respectively, into right eye. Vitreous from eyes plasma samples collected post at 1, 2, 6, 24, 48, 168, 336...
10026 Background: The HR-NBL1/SIOPEN trial randomised 2 essential treatment concepts: Randomisation R1 investigated BUMEL superiority (plenary session ASCO 2012), whilst the R2 randomisation tested benefits of adding subcutaneous interleukin (scIL2) to ch14.18/CHO mAB immunotherapy(IT) and 13 cis retinoic acid (13-cis RA). population reached target 400 patients (pts) in August 2013. Methods: After Rapid Cojec induction pts were (296 BuMel, 302 CEM) till 09/2010. Median follow up is 6.2...
To determine intravitreal and plasma concentrations retinal toxicity after transcorneal injection of 1 μg 2 topotecan (Hycamtin).Twelve healthy albino rabbits were included in this vivo experiment. Six anesthetized received a single (group A) or B) topotecan. Vitreous blood samples collected until 168 h. Left eyes treated with the same volume saline. Plasma vitreous levels determined by high-performance liquid chromatography. Area under concentration time curve (AUC) was calculated using...
10000 Background: The INES 99.4 trial (JCO 2009,27(7):1014-9) for MYCN amplified (MNA) infants using 6 courses of CBDCA-Vp16/CADO showed early progressions or non-response in 30%. Two-year overall survival (OS) was 30% (SE, 0.08) with median 12 months. Aims are to report risk factors and outcomes patients < 18 months MNA neuroblastoma treated on HR-NBL1/SIOPEN. Methods: From 2006-2022, INSS stages > 1 were eligible. All received Rapid Cojec induction, eventually 2 TVDs,...
Introduction: COVID-19 is considered a respiratory virosis in its classic form, although it may present with heterogeneous symptoms. Thoracic complications occur small percentage of patients. Our objective was to evaluate existing experience this disease and thoracic manifestations determine the real-world status care these Methods: This study retrospective, single-institution analysis group patients hospitalized acute post-acute pneumonia at Thomayer Hospital Prague period from December...
10527 Background: Evaluation of prognostic factors in high risk stage 4 neuroblastoma (HRNBL) patients (pts) treated with busulfan-melphalan (BUMEL) within HR-NBL1/SIOPEN. Methods: Between 2002-2009 (prior antiGD2 immunotherapy) BUMEL was given to 475 pts (275 males) 149 centres / 20 countries. Pts < 1year (yr) had MYCN amplification (MNA). After induction (COJEC ± 2-4 TVD) BUMEL/SCR (stem cell reinfusion) once achieved at least PR. Local control aimed gross surgical resection (achieved 76%)...